GB1563638A — 21-halogenopregnane compounds
Assigned to Novartis AG · Expires 1980-03-26 · 46y expired
What this patent protects
9 alpha ,21-Dihalo-11 beta ,17 alpha -dihydroxy-6 alpha -fluoro-16 alpha -methylpregna-1,4-diene -3,20-dione 17-esters of the formula <IMAGE> in which X1 is chlorine or fluorine, X2 is bromine or chlorine, and Ac is an acyl group derived from a carboxylic acid, are distingu…
USPTO Abstract
9 alpha ,21-Dihalo-11 beta ,17 alpha -dihydroxy-6 alpha -fluoro-16 alpha -methylpregna-1,4-diene -3,20-dione 17-esters of the formula <IMAGE> in which X1 is chlorine or fluorine, X2 is bromine or chlorine, and Ac is an acyl group derived from a carboxylic acid, are distinguished by high local antiinflammatory activity with a reduced systemic effect, for which reason they can be used in medicine to alleviate and control inflammatory states. They are obtained by conventional replacement of an organic 21-sulphonyloxy group by halogen X2.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.